Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 155

1.

The pharmacokinetics of nelfinavir in HIV-1-infected children.

van Heeswijk RP, Scherpbier HJ, de Koning LA, Heymans HS, Lange JM, Beijnen JH, Hoetelmans RM.

Ther Drug Monit. 2002 Aug;24(4):487-91.

PMID:
12142631
2.

Pharmacokinetics of nelfinavir in children: influencing factors and dose implications.

Bergshoeff AS, Fraaij PL, van Rossum AM, Wolfs TF, Geelen SP, de Groot R, Burger DM.

Antivir Ther. 2003 Jun;8(3):215-22.

PMID:
12924538
3.

Pharmacokinetics of nevirapine in HIV-infected children receiving an adult fixed-dose combination of stavudine, lamivudine and nevirapine.

Chokephaibulkit K, Plipat N, Cressey TR, Frederix K, Phongsamart W, Capparelli E, Kolladarungkri T, Vanprapar N.

AIDS. 2005 Sep 23;19(14):1495-9.

PMID:
16135903
4.

The pharmacokinetics of combination therapy with nelfinavir plus nevirapine.

Merry C, Barry MG, Mulcahy F, Ryan M, Tjia JF, Halifax KL, Breckenridge AM, Back DJ.

AIDS. 1998 Jul 9;12(10):1163-7.

PMID:
9677165
5.

Pharmacokinetics and pharmacodynamics of saquinavir in pediatric patients with human immunodeficiency virus infection.

Grub S, Delora P, Lüdin E, Duff F, Fletcher CV, Brundage RC, Kline MW, Calles NR, Schwarzwald H, Jorga K.

Clin Pharmacol Ther. 2002 Mar;71(3):122-30. Review.

PMID:
11907486
6.

Clinical pharmacokinetics of nelfinavir combined with efavirenz and stavudine during rescue treatment of heavily pretreated HIV-infected patients.

Regazzi MB, Villani P, Maserati R, Seminari E, Pan A, LoCaputo F, Gambarana E, Fiocchi C.

J Antimicrob Chemother. 2000 Mar;45(3):343-7.

PMID:
10702554
7.

Indinavir pharmacokinetics and parmacodynamics in children with human immunodeficiency virus infection.

Gatti G, Vigano' A, Sala N, Vella S, Bassetti M, Bassetti D, Principi N.

Antimicrob Agents Chemother. 2000 Mar;44(3):752-5.

8.

Pharmacokinetics of nelfinavir and its active metabolite, hydroxy-tert-butylamide, in infants perinatally infected with human immunodeficiency virus type 1.

Litalien C, Faye A, Compagnucci A, Giaquinto C, Harper L, Gibb DM, Jacqz-Aigrain E; Paediatric European Network for Treatment of AIDS Executive Committee.

Pediatr Infect Dis J. 2003 Jan;22(1):48-55.

PMID:
12544409
9.

Intracellular and plasma pharmacokinetics of nelfinavir and M8 in HIV-infected patients: relationship with P-glycoprotein expression.

Ford J, Cornforth D, Hoggard PG, Cuthbertson Z, Meaden ER, Williams I, Johnson M, Daniels E, Hsyu P, Back DJ, Khoo SH.

Antivir Ther. 2004 Feb;9(1):77-84.

PMID:
15040539
10.

High variability of indinavir and nelfinavir pharmacokinetics in HIV-infected patients with a sustained virological response on highly active antiretroviral therapy.

Goujard C, Legrand M, Panhard X, Diquet B, Duval X, Peytavin G, Vincent I, Katlama C, Leport C, Bonnet B, Salmon-Céron D, Mentré F, Taburet AM; COPHAR1-ANRS 102 Study Group.

Clin Pharmacokinet. 2005;44(12):1267-78.

PMID:
16372824
11.

Dose-escalating study of the safety and pharmacokinetics of nelfinavir in HIV-exposed neonates.

Rongkavilit C, van Heeswijk RP, Limpongsanurak S, Thaithumyanon P, Boonrod C, Hassink EA, Srigritsanapol A, Chuenyam T, Ubolyam S, Hoetelmans RM, Ruxrungtham K, Lange JM, Cooper DA, Phanuphak P.

J Acquir Immune Defic Syndr. 2002 Apr 15;29(5):455-63.

PMID:
11981361
12.

Pharmacokinetic characteristics of ritonavir, zidovudine, lamivudine, and stavudine in children with human immunodeficiency virus infection.

Fletcher CV, Yogev R, Nachman SA, Wiznia A, Pelton S, McIntosh K, Stanley K.

Pharmacotherapy. 2004 Apr;24(4):453-9.

PMID:
15098798
13.

Pharmacokinetic evaluation and short-term activity of stavudine, nevirapine, and nelfinavir therapy in HIV-1-infected adults.

Skowron G, Leoung G, Hall DB, Robinson P, Lewis R, Grosso R, Jacobs M, Kerr B, MacGregor T, Stevens M, Fisher A, Odgen R, Yen-Lieberman B.

J Acquir Immune Defic Syndr. 2004 Apr 1;35(4):351-8.

PMID:
15097151
14.

Population pharmacokinetics and pharmacodynamics of nelfinavir and its active metabolite M8 in HIV-1-infected children.

Crommentuyn KM, Scherpbier HJ, Kuijpers TW, Mathôt RA, Huitema AD, Beijnen JH.

Pediatr Infect Dis J. 2006 Jun;25(6):538-43.

PMID:
16732153
15.

Nelfinavir pharmacokinetics in stable human immunodeficiency virus-positive children: Pediatric AIDS Clinical Trials Group Protocol 377.

Floren LC, Wiznia A, Hayashi S, Jayewardene A, Stanley K, Johnson G, Nachman S, Krogstad P, Aweeka FT; Pediatric AIDS Clinical Trials Group 377 Protocol Team.

Pediatrics. 2003 Sep;112(3 Pt 1):e220-7.

PMID:
12949316
16.

Nelfinavir plasma levels under twice-daily and three-times-daily regimens: high interpatient and low intrapatient variability.

Marzolini C, Buclin T, Decosterd LA, Biollaz J, Telenti A.

Ther Drug Monit. 2001 Aug;23(4):394-8.

PMID:
11477322
17.

Therapeutic drug monitoring of indinavir and nelfinavir to assess adherence to therapy in human immunodeficiency virus-infected children.

van Rossum AM, Bergshoeff AS, Fraaij PL, Hugen PW, Hartwig NG, Geelen SP, Wolfs TF, Weemaes CM, De Groot R, Burger DM.

Pediatr Infect Dis J. 2002 Aug;21(8):743-7.

PMID:
12192162
19.

Antiviral activity of enteric-coated didanosine, stavudine, and nelfinavir versus zidovudine plus lamivudine and nelfinavir.

Gathe J Jr, Badaro R, Grimwood A, Abrams L, Klesczewski K, Cross A, McLaren C.

J Acquir Immune Defic Syndr. 2002 Dec 1;31(4):399-403.

PMID:
12447010
20.

Concentration-targeted phase I trials of atevirdine mesylate in patients with HIV infection: dosage requirements and pharmacokinetic studies. The ACTG 187 and 199 study teams.

Morse GD, Reichman RC, Fischl MA, Para M, Leedom J, Powderly W, Demeter LM, Resnick L, Bassiakos Y, Timpone J, Cox S, Batts D.

Antiviral Res. 2000 Jan;45(1):47-58.

PMID:
10774589

Supplemental Content

Support Center